Company Active LTD

Company profile

Novalgen Limited

NovalGen Breakthrough bispecific antibody therapies to treat cancer

NovalGen is an innovative immuno-oncology company focused on bispecific antibody approaches to fight cancer.

CRN

11621264

Founded

2018

Age

Overview

Legal name

NOVALGEN LIMITED

Region

London

Registered address

ARGYLE HOUSE LEVEL 3 NORTHSIDE

JOEL STREET

NORTHWOOD HILLS

MIDDLESEX

ENGLAND

HA6 1NW

Insolvency history

Corporate ownership

Updated 06 Jun 2026 16:52

1 level 2 ultimate controllers Controls 4

Company Active LTD

Novalgen Limited

CRN 11621264

Direct and ultimate controller Active LTD

Convergys Capital Limited

CRN 11339543

Direct and ultimate controller Active LTD

GHL Capital Ltd

CRN 16539120

Company events

Reference milestones and recent Companies House filing stream events.

7 events

30 Sep

2027

Accounts due

Accounts Due

Next accounts due date

27 Oct

2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

01 Jul

2026

Capital Allotment Shares

Capital

SH01 | Transaction MzUyOTgxNzA1MWFkaXF6a2N4

Published 01 Jul 2026 10:23

31 Dec

2025

Accounts filed

Accounts

Last accounts made up date

13 Oct

2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

15 Oct

2024

Confirmation Statement With No Updates

Confirmation-statement

CS01 | Transaction MzQzOTU5MTIzM2FkaXF6a2N4

Published 15 Oct 2024 01:12

14 Oct

2018

Incorporated

Inception

Company registered at Companies House

Public funding

1 award

First funded

2022

Funded years

2022

Age at first award

3 years

Projects

2022 Collaborative R&D Lead participant

First in class to first in human: Harnessing physiological regulation mechanisms to enhance safety and efficacy of next generation bispecific antibodies

1 Jun 2022 to 31 May 2024

Awarded

£590,648

Total cost £843,783

Therapeutic antibodies are biological therapies that have revolutionised the way we treat cancer and inflammatory diseases. Novalgen, an emerging immunotherapy company, has developed a novel and smart type of antibody that stops exerting its therapeutic activity once they have completed their activity. In so doing, the NovalGen technology offers a new gen...

Product types

Collaborative R&D